Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Gaining Insight Into the Management of Gastrointestinal Malignancies

December 28th 2020

Faculty from a recent Institutional Perspectives in Cancer webinar on gastrointestinal cancer hosted by the University of Kentucky discuss the current paradigms in hepatocellular carcinoma, colorectal cancer, and pancreatic cancer.

FDA Grants Orphan Drug Designation to Rintatolimod for Pancreatic Cancer

December 23rd 2020

December 23, 2020 - The FDA has granted an orphan drug designation to the mismatched, double-stranded RNA molecule rintatolimod for the treatment of patients with pancreatic cancer.

Dr. Kim on the Utility of Atezolizumab/Bevacizumab in HCC

December 21st 2020

Joseph Kim, MD, on the utility of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Dr. Patel Ongoing Research Efforts in Pancreatic Cancer

December 21st 2020

Reema A. Patel, MD, discusses ongoing research efforts in pancreatic cancer.

Dr. Patel on Findings From the NAPOLI-1 Trial in Pancreatic Cancer

December 18th 2020

Reema A. Patel, MD, discusses findings from the NAPOLI-1 trial in pancreatic cancer.

Dr. Kasi on Findings From the CRC-MRD Consortia in CRC

December 18th 2020

Pashtoon M. Kasi, MD, MS, discusses findings from the CRC-MRD Consortia in colorectal cancer.

Dr. Bahary on the Role of Pemigatinib in Biliary Tract Cancers

December 18th 2020

Nathan Bahary, MD, PhD, discusses the role of pemigatinib in biliary tract cancers.

FDA Grants Priority Review to Frontline Pembrolizumab/Chemo for Locally Advanced Unresectable or Metastatic Esophageal/GEJ Cancer

December 17th 2020

December 17, 2020 - The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy as a first-line treatment in patients with locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

Dr. Price on the Rationale for Sotorasib in Advanced Gastrointestinal Cancers

December 16th 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses the rationale to evaluate sotorasib in gastrointestinal cancers.

Second-Line Motixafortide Plus Pembrolizumab/Chemo Substantially Improves Survival in Stage IV PDAC

December 16th 2020

December 16, 2020 - The combination of motixafortide plus pembrolizumab and chemotherapy was found to result in a substantial improvement in overall survival, progression-free survival, and overall response rate when used as a second-line treatment in patients with stage IV pancreatic ductal adenocarcinoma.

Dr. Cavnar on Surgical Differences Between Right- and Left-Sided Tumors in CRC

December 15th 2020

Michael J. Cavnar, MD, discusses surgical differences between right- and left-sided tumors in colorectal cancer.

Dr. Pandalai on the Development of Peritoneal Carcinomatosis in CRC

December 15th 2020

Prakash Pandalai, MD, discusses the development of peritoneal carcinomatosis in colorectal cancer.

Dr. Kim on the Multidisciplinary Management of HCC

December 15th 2020

Joseph Kim, MD, discusses the multidisciplinary management of hepatocellular carcinoma.

MSI-H GI and Endometrial Tumors Show High Immunogenicity With Frameshift Mutations

December 14th 2020

December 14, 2020 - Microsatellite instability–high tumors in patients with endometrial, colorectal, and stomach carcinomas were found to be enriched in recurrent shared, immunogenic, tumor-specific frameshifts expressed on RNA and protein levels.

Biomarkers Drive ICIs in Colon Cancer

December 14th 2020

December 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.

Frontline Pembrolizumab Granted Positive EU Opinion in Metastatic MSI-H, dMMR CRC

December 11th 2020

December 11, 2020 - The European Medicine Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for pembrolizumab monotherapy for the frontline treatment of adult patients with metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Oncolytic Viral Therapy: A Unique Approach to Explore in GI Cancers

December 11th 2020

December 11, 2020 - Oncolytic viral therapy has been heavily investigated across oncology, but plenty of work still lies ahead to determine how this treatment approach can be applied in gastrointestinal malignancies.

Dr. Janjigian on the Emergence of New Treatment Options in Esophageal and Gastric Cancer

December 11th 2020

Yelena Y. Janjigian, MD, discusses the emergence of new treatment options in esophageal and gastric cancer.

Dr. Grothey on Investigational Combinations in MSI-High CRC

December 11th 2020

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Expert Expands on Recent Advances With Actionable Alterations Spanning GI Cancers

December 7th 2020

Nathan Bahary, MD, PhD, discusses the importance of seeking targetable alterations in GI cancers, as well as recent advancements in the space.